JP2018533601A - L−オルニチンフェニルアセテート製剤 - Google Patents
L−オルニチンフェニルアセテート製剤 Download PDFInfo
- Publication number
- JP2018533601A JP2018533601A JP2018524369A JP2018524369A JP2018533601A JP 2018533601 A JP2018533601 A JP 2018533601A JP 2018524369 A JP2018524369 A JP 2018524369A JP 2018524369 A JP2018524369 A JP 2018524369A JP 2018533601 A JP2018533601 A JP 2018533601A
- Authority
- JP
- Japan
- Prior art keywords
- plasma
- hours
- ornithine
- oral pharmaceutical
- oral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- LRSYFEZBIMVWRY-VWMHFEHESA-N (2s)-2,5-diaminopentanoic acid;2-phenylacetic acid Chemical compound NCCC[C@H](N)C(O)=O.OC(=O)CC1=CC=CC=C1 LRSYFEZBIMVWRY-VWMHFEHESA-N 0.000 title claims abstract description 96
- 238000002360 preparation method Methods 0.000 title abstract description 6
- 238000000034 method Methods 0.000 claims abstract description 67
- 208000007386 hepatic encephalopathy Diseases 0.000 claims abstract description 27
- 208000019423 liver disease Diseases 0.000 claims abstract description 23
- 206010020575 Hyperammonaemia Diseases 0.000 claims abstract description 19
- 208000019425 cirrhosis of liver Diseases 0.000 claims abstract description 14
- 230000007882 cirrhosis Effects 0.000 claims abstract description 13
- 208000028547 Inborn Urea Cycle disease Diseases 0.000 claims abstract description 9
- 208000030954 urea cycle disease Diseases 0.000 claims abstract description 9
- 208000007232 portal hypertension Diseases 0.000 claims abstract description 6
- 208000007788 Acute Liver Failure Diseases 0.000 claims abstract description 5
- 206010000804 Acute hepatic failure Diseases 0.000 claims abstract description 5
- 231100000836 acute liver failure Toxicity 0.000 claims abstract description 5
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 claims description 172
- JFLIEFSWGNOPJJ-JTQLQIEISA-N N(2)-phenylacetyl-L-glutamine Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)CC1=CC=CC=C1 JFLIEFSWGNOPJJ-JTQLQIEISA-N 0.000 claims description 85
- 229960003424 phenylacetic acid Drugs 0.000 claims description 72
- 239000003279 phenylacetic acid Substances 0.000 claims description 71
- 238000011282 treatment Methods 0.000 claims description 60
- 239000002552 dosage form Substances 0.000 claims description 27
- 239000008203 oral pharmaceutical composition Substances 0.000 claims description 25
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 claims description 24
- 229940049953 phenylacetate Drugs 0.000 claims description 24
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 22
- 238000006243 chemical reaction Methods 0.000 claims description 21
- 239000008183 oral pharmaceutical preparation Substances 0.000 claims description 10
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 239000006193 liquid solution Substances 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 230000002440 hepatic effect Effects 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- VEQOALNAAJBPNY-UHFFFAOYSA-N antipyrine Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 229960005222 phenazone Drugs 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000008188 pellet Substances 0.000 claims description 2
- 230000009969 flowable effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 56
- 238000009472 formulation Methods 0.000 abstract description 44
- 206010016654 Fibrosis Diseases 0.000 abstract description 13
- 238000001990 intravenous administration Methods 0.000 abstract description 9
- 210000004185 liver Anatomy 0.000 abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 208000030090 Acute Disease Diseases 0.000 abstract description 4
- 230000001154 acute effect Effects 0.000 abstract description 4
- 208000035475 disorder Diseases 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 24
- ZSDBFLMJVAGKOU-UHFFFAOYSA-N glycerol phenylbutyrate Chemical compound C=1C=CC=CC=1CCCC(=O)OCC(OC(=O)CCCC=1C=CC=CC=1)COC(=O)CCCC1=CC=CC=C1 ZSDBFLMJVAGKOU-UHFFFAOYSA-N 0.000 description 22
- 229940115145 ravicti Drugs 0.000 description 21
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 20
- 239000003814 drug Substances 0.000 description 15
- 210000002700 urine Anatomy 0.000 description 15
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 14
- 238000013270 controlled release Methods 0.000 description 14
- 229940079593 drug Drugs 0.000 description 13
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 11
- 229960003104 ornithine Drugs 0.000 description 11
- 150000003839 salts Chemical class 0.000 description 11
- 229910021529 ammonia Inorganic materials 0.000 description 10
- 238000013265 extended release Methods 0.000 description 10
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 10
- 229960000511 lactulose Drugs 0.000 description 10
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 10
- 239000008280 blood Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- GVNOKKGCPWLUOT-UHFFFAOYSA-N 2-phenylbutanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCC(C(O)=O)C1=CC=CC=C1 GVNOKKGCPWLUOT-UHFFFAOYSA-N 0.000 description 8
- 235000020937 fasting conditions Nutrition 0.000 description 8
- 229940100688 oral solution Drugs 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000029142 excretion Effects 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 239000002207 metabolite Substances 0.000 description 6
- 239000006186 oral dosage form Substances 0.000 description 6
- 230000002485 urinary effect Effects 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 210000005228 liver tissue Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010048962 Brain oedema Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010040047 Sepsis Diseases 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 208000006752 brain edema Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 230000036325 urinary excretion Effects 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 2
- 229940121848 Ammonia scavenger Drugs 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010010071 Coma Diseases 0.000 description 2
- 206010013496 Disturbance in attention Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- -1 L-ornithine cation Chemical class 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 208000034486 Multi-organ failure Diseases 0.000 description 2
- 208000010718 Multiple Organ Failure Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 201000009454 Portal vein thrombosis Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 208000010513 Stupor Diseases 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- IXUZXIMQZIMPSQ-ZBRNBAAYSA-N [(4s)-4-amino-4-carboxybutyl]azanium;(2s)-2-amino-4-hydroxy-4-oxobutanoate Chemical compound OC(=O)[C@@H](N)CCC[NH3+].[O-]C(=O)[C@@H](N)CC(O)=O IXUZXIMQZIMPSQ-ZBRNBAAYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 239000006194 liquid suspension Substances 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 108010049063 ornithylaspartate Proteins 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 210000003240 portal vein Anatomy 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 230000004143 urea cycle Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000007204 Brain death Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 206010009192 Circulatory collapse Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108010010256 Dietary Proteins Proteins 0.000 description 1
- 102000015781 Dietary Proteins Human genes 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000000624 Esophageal and Gastric Varices Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- NASRDENTZCCAPN-UHFFFAOYSA-N OC([Na])=O Chemical compound OC([Na])=O NASRDENTZCCAPN-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010056091 Varices oesophageal Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000009798 acute exacerbation Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940064746 ammonul Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 229940057372 buphenyl Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000011162 core material Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 208000024170 esophageal varices Diseases 0.000 description 1
- 201000010120 esophageal varix Diseases 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012734 extended-release (ER) formulation Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960002815 glycerol phenylbutyrate Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000006207 intravenous dosage form Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000009461 neurocognitive dysfunction Effects 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 229940000673 orphan drug Drugs 0.000 description 1
- 239000002859 orphan drug Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-M phenylacetate Chemical compound [O-]C(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-M 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- VPZRWNZGLKXFOE-UHFFFAOYSA-M sodium phenylbutyrate Chemical compound [Na+].[O-]C(=O)CCCC1=CC=CC=C1 VPZRWNZGLKXFOE-UHFFFAOYSA-M 0.000 description 1
- 229960002232 sodium phenylbutyrate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
本出願は、2015年11月13日出願の米国仮特許出願第62/255,300号、2016年1月8日出願の米国仮特許出願第62/276,754号、および2016年4月19日出願の米国特許出願第15/133,087号に基づく優先権の利益を主張するものであり、これらの出願は全て、参照により全体が本明細書に明示的に組み込まれる。
本出願は、L−オルニチンフェニルアセテートの経口製剤を含む医薬組成物、ならびに、様々な急性および慢性の肝疾患ならびに障害、例えば急性肝不全、肝硬変、肝代償不全、門脈圧亢進症、肝性脳症を有する患者、または尿素サイクル異常症患者の高アンモニア血症を処置するための投与の方法および使用に関する。
慢性肝疾患は、肝組織が時間と共に漸進的に破壊され、それにより、健常で再生する肝組織が瘢痕および壊死組織にゆっくりと置き換えられることを特徴とする。これは肝硬変として知られている。正常な肝機能が損なわれ、瘢痕組織により、肝臓を通る血流が次第に減少する。正常な再生する肝組織が失われるため、栄養素、ホルモン、薬物、および毒素が効果的に処理されなくなる。これは、腸管を通して吸収されるタンパク質の異常なクリアランスによるアンモニアの蓄積、血液中にビリルビンを蓄積させ黄疸の生成につながる異常排泄、腹部における流体の蓄積(腹水貯留)につながる類洞圧の増加、ならびに、瘢痕化した肝組織が血流への障壁となり、門脈血圧の増加および食道静脈瘤につながる門脈圧亢進症(および門脈大循環シャント)を含む症状をもたらし得る。
本明細書において使用される節の見出しは、構成のみを目的とするものであり、記載される主題を限定するものと解釈されてはならない。
AUC:曲線下面積
AUC0−t:時間=0(ゼロ)から最後の数量化可能な濃度の時間までの濃度対時間曲線下面積
AUC0−inf:無限時間まで外挿した血漿濃度時間曲線下面積
CL:全血漿クリアランス
C12:薬物投与後12時間における薬物濃度
Cmax:最大血漿濃度
F:バイオアベイラビリティ絶対値(%)
hr:時間
IR:即時放出
ORN:オルニチン
PAA:フェニル酢酸(または共役塩基であるフェニルアセテート)
PAGN:フェニルアセチルグルタミン
PD:薬力学的な
PK:薬物動態学的な
本開示のいくつかの実施形態は、約0.1g〜約10gの投与量のL−オルニチンフェニルアセテートと、1種または複数種の薬学的に許容される賦形剤もしくは担体とを含む、経口医薬製剤に関する。いくつかの実施形態では、本製剤は、投与の際にL−オルニチンフェニルアセテートの即時放出プロファイルをもたらす(例えば、液体溶液または懸濁液の形態における即時放出経口製剤)。他の実施形態は、制御放出または長期放出のプロファイルをもたらす。好ましい実施形態において、本医薬製剤は、経口医薬製剤である。いくつかの実施形態では、L−オルニチンフェニルアセテートは、約0.5g、約1g、約1.5g、約2g、約2.5g、約3g、約3.5g、約4g、約4.5g、約5g、約5.5g、約6g、約6.5g、約7g、約7.5g、約8g、約8.5g、約9g、約9.5g、もしくは約10gの投与量、または前出の値のいずれか2つによって定義される投与量範囲(例えば、約1g〜約9g、約2g〜約8g、約3g〜約7g、約4g〜約6g、約1g〜約6g、約1g〜約5g、約1g〜約4g、約1g〜約3g、約2g〜約6g、約2g〜約5g、もしくは約2g〜約4g)である。一実施形態において、経口投与量は、約2.5gである。別の実施形態では、経口投与量は、約5gである。
本開示のいくつかの実施形態は、高アンモニア血症の処置または寛解を必要とする対象に、有効量のL−オルニチンフェニルアセテートを含む医薬製剤、特に本明細書に記載の経口医薬製剤を経口投与することを含む、高アンモニア血症を処置または寛解する方法に関する。いくつかの実施形態では、対象は急性肝不全または慢性肝疾患を有する。いくつかの実施形態では、対象は肝硬変または肝代償不全を有する。いくつかのそのような実施形態では、慢性肝疾患または肝硬変は、チャイルド・ピュークラスA、B、またはCの分類を有する。いくつかの実施形態は、チャイルド・ピュー分類Aの肝疾患を有する対象を特定することと、次に、本明細書に記載の組成物を投与することとを含む。いくつかの実施形態は、チャイルド・ピュー分類Bの肝疾患を有する対象を特定することと、次に、本明細書に記載の組成物を投与することとを含む。いくつかの実施形態では、対象は肝性脳症を有する。いくつかの実施形態は、チャイルド・ピュー分類Cの肝疾患を有する対象を特定することと、次に、本明細書に記載の組成物を投与することとを含む。さらにいくつかの実施形態では、対象は門脈圧亢進症を有する。いくつかの実施形態では、対象は尿素サイクル異常症を有する。いくつかの他の実施形態では、対象は、ラクツロースの処置を最近中断したものであり、例えば、対象は、ラクツロースの処置を1日間、2日間、3日間、4日間、5日間、6日間、1週間、2週間、3週間、4週間、またはそれ以上にわたり中断したものである。
(実施例)
非盲検、5剤5期、単回用量、クロスオーバーの第1相ヒト臨床研究を行って、L−オルニチンフェニルアセテートの長期放出経口剤形3種を単回投薬した後のフェニル酢酸およびフェニルアセチルグルタミンの薬物動態を、フェニル酢酸のプロドラッグであるRAVICTI(登録商標)(グリセロールフェニル酪酸)と比較して評価した。この研究では、単回用量のL−オルニチンフェニルアセテートの即時放出経口溶液と比較した、単回用量のL−オルニチンフェニルアセテートの長期放出経口剤形3種の薬物動態および安全性も比較した。
処置A、B、C、またはD(L−オルニチンフェニルアセテートまたはRAVICTI(登録商標)の長期放出(ER)製剤)が投与された投薬期間において、静脈血試料(各5mL)を次の時点:投薬直前(15分以内)、それから投薬後0.5時間、1時間、1.5時間、2時間、2.5時間、3時間、3.5時間、4時間、5時間、6時間、8時間、10時間、12時間、16時間、20時間、および24時間で採取した。L−オルニチンフェニルアセテートの即時放出製剤が投与された投薬期間(期間5)では、静脈血試料(各5mL)を次の時点:投薬直前(15分以内)、それから投薬後0.25時間、0.5時間、0.75時間、1時間、1.5時間、2時間、2.5時間、3時間、3.5時間、4時間、4.5時間、5時間、6時間、7時間、8時間、10時間、および12時間で採取した。
有効性が認められたLC−MS/MS法を使用して、血漿試料中のフェニル酢酸(PAA)、フェニルアセチルグルタミン(PAGN)、およびオルニチン(ORN)の濃度を分析した。有効性が認められたLC−MS/MS法を使用して、全ての尿試料中のPAGNの濃度を分析した。
薬物動態:試験薬のそれぞれを単回経口投薬した後のフェニルアセテート、オルニチン、およびフェニルアセチルグルタミンの血漿濃度対時間プロファイルを、非コンパートメントPK法によって分析した。決定した薬物動態パラメータは、Cmax、tmax、AUC0−t、AUC0−∞、C12、およびt1/2を含む。各採取間隔および24時間間隔全体にわたる、尿中に排泄されたPAGNの量、および尿中にPAGNとして排泄されたPAA用量の割合もまた決定した。
この実施例では、単回用量の部分的ランダム化臨床研究を行って、肝硬変(チャイルド・ピュークラスA)を有する5人の対象において、摂食条件下、絶食条件下、またはラクツロース中断後の絶食条件下で投与された5gのL−オルニチンフェニルアセテート経口溶液を評価した。その目的は、肝硬変(チャイルド・ピュークラスA)を有する対象において、摂食条件下、絶食条件下、またはラクツロース中断後の絶食条件下で5gの単回用量のL−オルニチンフェニルアセテート経口溶液を投与した後のPAAおよびPAGN薬物動態を、絶食条件下で5gの単回静脈内用量のL−オルニチンフェニルアセテートと比較して決定することである。
各経口投薬(処置A、B、およびD)の後、静脈血試料(各5mL)を次の時点:投薬直前(15分以内)、それから投薬後0.25時間、0.5時間、0.75時間、1時間、1.5時間、2時間、2.5時間、3時間、3.5時間、4時間、5時間、6時間、7時間、8時間、10時間、および12時間で採取した。処置D(投薬期間4)に関しては、投薬後24時間で追加の血液試料を取得した。静脈内投薬(処置C)の後、静脈血試料(各5mL)を次の時点:注入開始の直前(15分以内)、それから注入開始後0.5時間、そして注入終了の直前、その後、注入終了後10分、20分、30分、45分、および60分、それから注入終了後1.5時間、2時間、2.5時間、3時間、4時間、6時間、8時間、10時間、12時間、および24時間で採取した。
Claims (51)
- 約0.1g〜約10gの経口投与量のL−オルニチンフェニルアセテートと、1種または複数種の薬学的に許容される賦形剤または担体とを含む、経口医薬製剤。
- 経口投与の際にL−オルニチンフェニルアセテートの即時放出プロファイルをもたらす、請求項1に記載の経口医薬製剤。
- L−オルニチンフェニルアセテートの前記経口投与量が約2.5gである、請求項1に記載の経口医薬製剤。
- L−オルニチンフェニルアセテートの前記経口投与量が約5gである、請求項1に記載の経口医薬製剤。
- 単一の単位剤形である、請求項1から4のいずれか一項に記載の経口医薬製剤。
- 2つ以上の単位剤形である、請求項1から5のいずれか一項に記載の経口医薬製剤。
- 前記単位剤形が、錠剤、カプセル剤、丸剤、ペレット、流動性粉末、または液体である、請求項6に記載の経口医薬製剤。
- 前記単位剤形が液体溶液である、請求項7に記載の経口医薬製剤。
- 24時間で約30%超のフェニルアセテートからフェニルアセチルグルタミンへの変換をもたらす、請求項1から8のいずれか一項に記載の経口医薬製剤。
- 24時間で約50%超のフェニルアセテートからフェニルアセチルグルタミンへの変換をもたらす、請求項9に記載の経口医薬製剤。
- 24時間で約80%超のフェニルアセテートからフェニルアセチルグルタミンへの変換をもたらす、請求項10に記載の経口医薬製剤。
- 高アンモニア血症の処置または寛解を必要とする対象に、請求項1から11のいずれか一項に記載の経口医薬製剤を経口投与することを含む、高アンモニア血症を処置または寛解するための方法。
- 前記経口医薬製剤が、約10μg/mL〜約120μg/mLのフェニル酢酸の血漿Cmaxをもたらす、請求項12に記載の方法。
- フェニル酢酸の血漿Cmaxが、約20μg/mL〜約110μg/mLである、請求項13に記載の方法。
- 前記経口医薬製剤が、約10μg/mL〜約80μg/mLのフェニルアセチルグルタミンの血漿Cmaxをもたらす、請求項12から14のいずれか一項に記載の方法。
- フェニルアセチルグルタミンの血漿Cmaxが、約20μg/mL〜約45μg/mLである、請求項15に記載の方法。
- 高アンモニア血症の処置または寛解を必要とする対象に、L−オルニチンフェニルアセテートを含む医薬製剤を経口投与することを含み、前記投与が、約10μg/mL〜約150μg/mLの範囲のフェニル酢酸の血漿Cmaxをもたらす、高アンモニア血症を処置または寛解するための方法。
- フェニル酢酸の血漿Cmaxレベルが、約20μg/mL〜約140μg/mLである、請求項17に記載の方法。
- フェニル酢酸の血漿Cmaxレベルが、約30μg/mL〜約130μg/mLである、請求項18に記載の方法。
- フェニル酢酸の血漿Cmaxレベルが、約40μg/mL〜約120μg/mLである、請求項19に記載の方法。
- 前記投与が、約5μg/mL〜約100μg/mLの範囲のフェニルアセチルグルタミンの血漿Cmaxをもたらす、請求項17から20のいずれか一項に記載の方法。
- フェニルアセチルグルタミンの血漿Cmaxが、約10μg/mL〜約80μg/mLである、請求項21に記載の方法。
- フェニルアセチルグルタミンの血漿Cmaxが、約20μg/mL〜約60μg/mLである、請求項22に記載の方法。
- フェニルアセチルグルタミンの血漿Cmaxが、約25μg/mL〜約50μg/mLである、請求項23に記載の方法。
- 高アンモニア血症の処置または寛解を必要とする対象に、L−オルニチンフェニルアセテートを含む医薬製剤を経口投与することを含み、前記投与が、約100hr*μg/mL〜約1000hr*μg/mLの範囲のフェニル酢酸の血漿AUC0−tまたはAUC0−infをもたらす、高アンモニア血症を処置または寛解するための方法。
- フェニル酢酸の血漿AUC0−tまたはAUC0−infが、約200hr*μg/mL〜約800hr*μg/mLである、請求項25に記載の方法。
- フェニル酢酸の血漿AUC0−tまたはAUC0−infが、約350hr*μg/mL〜約600hr*μg/mLである、請求項26に記載の方法。
- フェニル酢酸の血漿AUC0−tまたはAUC0−infが、約400hr*μg/mL〜約550hr*μg/mLである、請求項26に記載の方法。
- フェニルアセチルグルタミンの血漿AUC0−tまたはAUC0−infが、約25hr*μg/mL〜約500hr*μg/mLである、請求項25から28のいずれか一項に記載の方法。
- フェニルアセチルグルタミンの血漿AUC0−tが、約50hr*μg/mL〜約300hr*μg/mLである、請求項29に記載の方法。
- フェニルアセチルグルタミンの血漿AUC0−tが、約100hr*μg/mL〜約200hr*μg/mLである、請求項30に記載の方法。
- フェニルアセチルグルタミンの血漿AUC0−tが、約120hr*μg/mL〜約180hr*μg/mLである、請求項31に記載の方法。
- フェニルアセチルグルタミンの血漿AUC0−infが、約50hr*μg/mL〜約400hr*μg/mLである、請求項29に記載の方法。
- フェニルアセチルグルタミンの血漿AUC0−infが、約75hr*μg/mL〜約300hr*μg/mLである、請求項33に記載の方法。
- フェニルアセチルグルタミンの血漿AUC0−infが、約100hr*μg/mL〜約250hr*μg/mLである、請求項34に記載の方法。
- フェニルアセチルグルタミンの血漿AUC0−infが、約150hr*μg/mL〜約200hr*μg/mLである、請求項35に記載の方法。
- 前記医薬製剤が、請求項1から11のいずれか一項から選択される、請求項25から36のいずれか一項に記載の方法。
- 前記対象が急性肝不全または慢性肝疾患を有する、請求項12から37のいずれか一項に記載の方法。
- 前記対象が肝硬変または肝代償不全を有する、請求項38に記載の方法。
- 慢性肝疾患または肝硬変が、チャイルド・ピュークラスA、B、またはCの分類を有する、請求項38または39に記載の方法。
- 前記対象が肝性脳症を有する、請求項12から37のいずれか一項に記載の方法。
- 前記対象が門脈圧亢進症を有する、請求項12から37のいずれか一項に記載の方法。
- 前記対象が尿素サイクル異常症を有する、請求項12から37のいずれか一項に記載の方法。
- 前記経口医薬製剤がL−オルニチンフェニルアセテートの即時放出をもたらす、請求項12から43のいずれか一項に記載の方法。
- 前記経口医薬製剤が、少なくとも1日1回投与される、請求項12から44のいずれか一項に記載の方法。
- 前記経口医薬製剤が、1日2回以上投与される、請求項12から45のいずれか一項に記載の方法。
- 前記投与が、24時間で約30%超のフェニルアセテートからフェニルアセチルグルタミンへの変換をもたらす、請求項12から46のいずれか一項に記載の方法。
- 前記投与が、24時間で約50%超のフェニルアセテートからフェニルアセチルグルタミンへの変換をもたらす、請求項47に記載の方法。
- 前記投与が、24時間で約80%超のフェニルアセテートからフェニルアセチルグルタミンへの変換をもたらす、請求項48に記載の方法。
- それぞれが約0.1g〜約2gのL−オルニチンフェニルアセテートを含む1〜5つの単位剤形を経口投与することを含む、請求項12から49のいずれか一項に記載の方法。
- それぞれが約0.5g〜約1.25gのL−オルニチンフェニルアセテートを含む2〜4つの単位剤形を経口投与することを含む、請求項12から50のいずれか一項に記載の方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021213640A JP2022058446A (ja) | 2015-11-13 | 2021-12-28 | L-オルニチンフェニルアセテート製剤 |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562255300P | 2015-11-13 | 2015-11-13 | |
US62/255,300 | 2015-11-13 | ||
US201662276754P | 2016-01-08 | 2016-01-08 | |
US62/276,754 | 2016-01-08 | ||
US15/133,087 US20160338982A1 (en) | 2015-04-20 | 2016-04-19 | Formulations of l-ornithine phenylacetate |
US15/133,087 | 2016-04-19 | ||
PCT/US2016/061678 WO2017083758A1 (en) | 2015-11-13 | 2016-11-11 | Formulation of l-ornithine phenylacetate |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021213640A Division JP2022058446A (ja) | 2015-11-13 | 2021-12-28 | L-オルニチンフェニルアセテート製剤 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2018533601A true JP2018533601A (ja) | 2018-11-15 |
JP2018533601A5 JP2018533601A5 (ja) | 2019-12-19 |
JP7294807B2 JP7294807B2 (ja) | 2023-06-20 |
Family
ID=58695607
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018524369A Active JP7294807B2 (ja) | 2015-11-13 | 2016-11-11 | L-オルニチンフェニルアセテート製剤 |
JP2021213640A Pending JP2022058446A (ja) | 2015-11-13 | 2021-12-28 | L-オルニチンフェニルアセテート製剤 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021213640A Pending JP2022058446A (ja) | 2015-11-13 | 2021-12-28 | L-オルニチンフェニルアセテート製剤 |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP3373923A4 (ja) |
JP (2) | JP7294807B2 (ja) |
KR (1) | KR20180086431A (ja) |
CN (2) | CN108366983A (ja) |
AU (2) | AU2016353350B2 (ja) |
BR (1) | BR112018009349A8 (ja) |
CA (1) | CA3004331A1 (ja) |
IL (1) | IL258630B2 (ja) |
MX (2) | MX2018005088A (ja) |
RU (1) | RU2018113801A (ja) |
SG (1) | SG11201802987UA (ja) |
WO (1) | WO2017083758A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
WO2019036471A1 (en) | 2017-08-14 | 2019-02-21 | Axcella Health Inc. | AMINO ACIDS BRANCHED FOR THE TREATMENT OF LIVER DISEASE |
AR115585A1 (es) | 2018-06-20 | 2021-02-03 | Axcella Health Inc | Composiciones y métodos para el tratamiento de la infiltración de grasa en músculo |
CA3157376A1 (en) * | 2019-10-16 | 2021-04-22 | Ocera Therapeutics, Inc. | Dosages and uses of ornithine phenylacetate for treating hyperammonemia |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012529523A (ja) * | 2009-06-08 | 2012-11-22 | ユーシーエル ビジネス ピーエルシー | L−オルニチンフェニル酢酸塩を用いる門脈圧亢進の治療及び肝機能の修復 |
JP2018513171A (ja) * | 2015-04-20 | 2018-05-24 | オセラ セラピューティクス, インコーポレイテッド | L−オルニチンフェニルアセテート製剤 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
GB0426141D0 (en) * | 2004-11-26 | 2004-12-29 | Ucl Biomedica Plc | Treatment |
CN102512408B (zh) | 2004-11-26 | 2015-11-25 | Ucl商业有限公司 | 用于治疗肝性脑病的含有鸟氨酸和苯基乙酸或苯基丁酸的组合物 |
DE102007009243A1 (de) * | 2007-02-22 | 2008-09-18 | Evonik Röhm Gmbh | Pellets mit einer Wirkstoff-Matrix und einem Polymerüberzug, sowie ein Verfahren zur Herstellung der Pellets |
AU2015221466B2 (en) | 2009-04-03 | 2017-02-02 | Ocera Therapeutics, Inc. | L-ornithine phenyl acetate and methods of making thereof |
EP2413924B1 (en) * | 2009-04-03 | 2017-09-27 | Ocera Therapeutics, Inc. | L-ornithine phenyl acetate and methods of making thereof |
AU2014250643B2 (en) | 2009-06-08 | 2016-07-14 | Ocera Therapeutics, Inc. | Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate |
EP2625162B1 (en) * | 2010-10-06 | 2019-03-13 | Ocera Therapeutics, Inc. | Methods of making l-ornithine phenyl acetate |
CN103705490B (zh) * | 2013-10-31 | 2016-08-17 | 蚌埠丰原医药科技发展有限公司 | 一种门冬氨酸鸟氨酸的缓释制剂及其制备工艺 |
-
2016
- 2016-11-11 BR BR112018009349A patent/BR112018009349A8/pt not_active Application Discontinuation
- 2016-11-11 CA CA3004331A patent/CA3004331A1/en active Pending
- 2016-11-11 JP JP2018524369A patent/JP7294807B2/ja active Active
- 2016-11-11 AU AU2016353350A patent/AU2016353350B2/en not_active Ceased
- 2016-11-11 CN CN201680066488.5A patent/CN108366983A/zh active Pending
- 2016-11-11 SG SG11201802987UA patent/SG11201802987UA/en unknown
- 2016-11-11 RU RU2018113801A patent/RU2018113801A/ru not_active Application Discontinuation
- 2016-11-11 EP EP16865158.6A patent/EP3373923A4/en not_active Withdrawn
- 2016-11-11 KR KR1020187016373A patent/KR20180086431A/ko not_active Application Discontinuation
- 2016-11-11 MX MX2018005088A patent/MX2018005088A/es unknown
- 2016-11-11 WO PCT/US2016/061678 patent/WO2017083758A1/en active Application Filing
- 2016-11-11 CN CN202111062923.6A patent/CN113768863A/zh active Pending
-
2018
- 2018-04-11 IL IL258630A patent/IL258630B2/en unknown
- 2018-04-25 MX MX2022001517A patent/MX2022001517A/es unknown
-
2021
- 2021-12-21 AU AU2021290236A patent/AU2021290236A1/en not_active Abandoned
- 2021-12-28 JP JP2021213640A patent/JP2022058446A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012529523A (ja) * | 2009-06-08 | 2012-11-22 | ユーシーエル ビジネス ピーエルシー | L−オルニチンフェニル酢酸塩を用いる門脈圧亢進の治療及び肝機能の修復 |
JP2018513171A (ja) * | 2015-04-20 | 2018-05-24 | オセラ セラピューティクス, インコーポレイテッド | L−オルニチンフェニルアセテート製剤 |
Also Published As
Publication number | Publication date |
---|---|
CA3004331A1 (en) | 2017-05-18 |
MX2018005088A (es) | 2019-05-16 |
IL258630B1 (en) | 2023-04-01 |
IL258630A (en) | 2018-06-28 |
EP3373923A4 (en) | 2019-07-03 |
SG11201802987UA (en) | 2018-05-30 |
IL258630B2 (en) | 2023-08-01 |
EP3373923A1 (en) | 2018-09-19 |
CN113768863A (zh) | 2021-12-10 |
WO2017083758A1 (en) | 2017-05-18 |
BR112018009349A8 (pt) | 2019-02-26 |
MX2022001517A (es) | 2022-11-16 |
BR112018009349A2 (pt) | 2018-11-13 |
KR20180086431A (ko) | 2018-07-31 |
AU2016353350B2 (en) | 2021-09-23 |
CN108366983A (zh) | 2018-08-03 |
RU2018113801A (ru) | 2019-12-16 |
JP2022058446A (ja) | 2022-04-12 |
AU2021290236A1 (en) | 2022-02-10 |
AU2016353350A1 (en) | 2018-05-10 |
JP7294807B2 (ja) | 2023-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220202755A1 (en) | Formulations of l-ornithine phenylacetate | |
JP2022058446A (ja) | L-オルニチンフェニルアセテート製剤 | |
US20220184014A1 (en) | Formulations of l-ornithine phenylacetate | |
JP6636108B2 (ja) | アスタキサンチン抗炎症性相乗的組み合わせ | |
NL193307C (nl) | Bruispreparaat met analgetische werkzaamheid. | |
JP2002521329A (ja) | フェニルアセチルグルタミン、フェニルアセチルイソグルタミンおよび/または酢酸フェニルの投与のための治療管理 | |
KR20120138229A (ko) | 정맥내 투여용 이부프로펜을 이용한 중증 환자의 치료 | |
KR20120089623A (ko) | 정맥내 투여용 이부프로펜을 이용한 환자의 치료 | |
JP5128003B2 (ja) | 腹膜透析患者用の経口医薬組成物及びその用法 | |
WO2023245470A1 (zh) | Mdp类似物在制备用于治疗炎症性肠病的药物中的用途 | |
JP6935930B2 (ja) | 生薬成分を含む肺高血圧症の予防又は治療剤 | |
TW201720461A (zh) | 預防或治療脂肪胰、改善脂肪胰引起的胰病變、糖尿病或其他相關病症之組合物及方法 | |
JP2021024835A (ja) | 小腸潰瘍改善剤 | |
WO2000076496A1 (fr) | Composes facilitant l'accumulation de medicaments dans des tissus tumoraux | |
IL227742A (en) | Plumzanil complexes, compounds containing them and their uses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191108 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191108 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20201012 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201110 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210202 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210329 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210428 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20210428 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20210831 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211228 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20211228 |
|
C11 | Written invitation by the commissioner to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C11 Effective date: 20220118 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20220209 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20220301 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20220308 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20220401 |
|
C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20220405 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20230314 |
|
C27C | Written answer of applicant after an oral proceeding |
Free format text: JAPANESE INTERMEDIATE CODE: C2721 Effective date: 20230314 |
|
C876 | Explanation why request for accelerated appeal examination is justified |
Free format text: JAPANESE INTERMEDIATE CODE: C876 Effective date: 20230315 |
|
C305 | Report on accelerated appeal examination |
Free format text: JAPANESE INTERMEDIATE CODE: C305 Effective date: 20230316 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20230322 |
|
C23 | Notice of termination of proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C23 Effective date: 20230404 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230608 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7294807 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |